Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors.
The diagnosis and treatment of erectile dysfunction has changed dramatically since the availability of safe and effective oral therapies. Unfortunately, not all men can be adequately treated in this way, and might require more invasive testing to diagnose and treat the specific cause of their dysfunction. This review looks at the tests and strategies available for men who cannot be treated by oral therapy alone.
Jacobsohn
Kenneth
K
Department of Urology, University of Texas Health Science Center and MD Anderson Cancer Center, Houston, Texas 77030, USA.
Wang
Run
R
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000792:Angiography; D001783:Blood Flow Velocity; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D010413:Penis / Q000098:blood supply / Q000000981:diagnostic imaging; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human